Zydus Lifesciences Ltd's Q3FY25 Quarter Results
- 06 Feb 2025
Result Summary
- Zydus Lifesciences Ltd reported a 0.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.3%.
- Its expenses for the quarter were up by 2.7% QoQ and 14.5% YoY.
- The net profit increased 11.5% QoQ and increased 29.9% YoY.
- The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 10.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 5326.60 | 5305.20 | 4542.90 | 0.4% | 17.3% |
Total Expenses | 4142.50 | 4034.30 | 3617.40 | 2.7% | 14.5% |
Profit Before Tax | 1184.10 | 1270.90 | 925.50 | -6.8% | 27.9% |
Tax | 179.50 | 373.10 | 213.80 | -51.9% | -16.0% |
Profit After Tax | 1026.20 | 920.20 | 789.90 | 11.5% | 29.9% |
Earnings Per Share | 10.20 | 9.10 | 7.80 | 12.1% | 30.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zydus Lifesciences Ltd, a prominent player in the pharmaceutical industry, is known for its extensive portfolio of healthcare products and services. The company primarily operates in the sectors of pharmaceuticals, diagnostics, and active pharmaceutical ingredients (APIs). Zydus is recognized for its focus on innovation and commitment to addressing pressing healthcare needs through its broad range of products, which includes therapeutic drugs, vaccines, and over-the-counter products. While specific recent major developments for Zydus Lifesciences are not provided in this report, the company consistently emphasizes research and development as a core part of its business strategy.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Zydus Lifesciences Ltd reported a total income of ₹5,326.60 crores. This represents a quarter-over-quarter (QoQ) increase of 0.4% from the second quarter of fiscal year 2025 (Q2FY25), where total income was ₹5,305.20 crores. On a year-over-year (YoY) basis, the total income saw a significant increase of 17.3% compared to ₹4,542.90 crores in the third quarter of the fiscal year 2024 (Q3FY24). This growth in revenue indicates the company's ability to expand its market presence and enhance its sales performance over the period.
Profitability
For Q3FY25, Zydus Lifesciences Ltd recorded a profit before tax of ₹1,184.10 crores, which reflects a decrease of 6.8% from the previous quarter (Q2FY25) where it was ₹1,270.90 crores. However, when compared to the same quarter in the previous year (Q3FY24), there is a substantial increase of 27.9% from ₹925.50 crores. The tax expense for Q3FY25 was ₹179.50 crores, demonstrating a significant reduction of 51.9% QoQ and 16.0% YoY. Consequently, the profit after tax increased to ₹1,026.20 crores, up by 11.5% QoQ and 29.9% YoY, reflecting strong profitability growth. The earnings per share for the quarter stood at ₹10.20, marking a 12.1% QoQ increase and a 30.8% YoY rise.
Operating Metrics
The total expenses for Zydus Lifesciences in Q3FY25 were ₹4,142.50 crores, which is a 2.7% increase from Q2FY25's total expenses of ₹4,034.30 crores. On a YoY basis, total expenses rose by 14.5% from ₹3,617.40 crores in Q3FY24. This increase in expenses is reflective of the company's operational scale and cost management over the period. Despite the rise in expenses, the company has managed to maintain profitability, as evidenced by the increased profit margins. The earnings per share, a key indicator of shareholder value, also showed a positive trend, increasing both QoQ and YoY. These operational metrics highlight the company's efficiency in managing its resources and generating value for its shareholders.
